| What is RSS feed? | About Us |
 |
 Search Score: 5/10
Source: www.iht.com --- 30 days ago
Schering-Plough and Merck's cholesterol Drug Vytorin doesn't lower the risk of major heart valve problems and need for related surgical procedures, according to a large-scale study. ... Source: www.moreover.com --- 23 days ago
MONTREAL - Ambrilia Biopharma Inc. said Monday that partner Merck & Co Inc. has decided to suspend development of the HIV Drug MK-8122. ... Source: www.moreover.com --- 30 days ago
In the latest disappointment over cholesterol pill Vytorin, a major European study in patients with heart valve disease found the Drug did not prevent worsening of the disease or lower the need for valve surgery. ... Source: www.moreover.com --- 17 days ago
Extract not available. ... Source: www.marketwatch.com --- 6 days ago
(Adds Orchid Chemicals comments.) BANGALORE (MarketWatch) -- Indian drugmaker Orchid Chemicals & Pharmaceuticals Ltd. Wednesday said it would develop an anticoagulant Drug candidate initially discovered and developed through Phase I by U.S.-based Merck & Co. Inc. . As a part of this development, Orchid has invested in Diakron Pharmaceuticals Inc., a U.S.-based Drug discovery and development company, which has an exclusive license agreement with Merck for the Drug. ...
Source: sanjose.bizjournals.com --- 19 days ago
Gilead Sciences Inc. and Merck & Co. Inc. said Friday they will collaborate on the distribution of HIV Drug Atripla to 12 countries, primarily in Latin America and the Asia-Pacific region. (GILD) (MRK) ... Source: www.newscientist.com --- 1 day ago
Pharmaceutical giant accused of using a Drug trial to introduce primary-care physicians to the painkiller Vioxx ... Source: www.moreover.com --- 17 days ago
PSL Group Aug 3 2008 7:46AM GMT ... Source: www.moreover.com --- 6 days ago
Biotech Intelligence Aug 14 2008 4:47AM GMT ... Source: www.moreover.com --- 7 days ago
Therapeutics Daily Aug 13 2008 12:35PM GMT ... Source: www.moreover.com --- 6 days ago
Nasdaq Aug 14 2008 6:22AM GMT ... Source: www.moreover.com --- 45 days ago
The Hindu Jul 6 2008 12:12PM GMT ... Source: www.moreover.com --- 38 days ago
PSL Group Jul 12 2008 5:43AM GMT ...
Source: www.moreover.com --- 50 days ago
TMC Net Jul 1 2008 6:50AM GMT ... Source: www.moreover.com --- 36 days ago
FierceBiotech Jul 15 2008 10:04PM GMT ... Source: www.earthtimes.org --- 30 days ago
New York - US pharmaceutical firm Merck & Co dropped on Wall Street Monday ahead of its earnings release after a study showed a cholesterol-lowering Drug did not prevent complications from heart- valve disease and was linked to higher cancer rates. T... ...
Find more results for Merck Drug on RSSMicro.com |
Copyright © 2008 RSSMicro.com
AFP - The German pharmaceutical and chemical group Merck posted Wednesday strong second quarter results despite negative foreign exchange effects, it said in a statement. ...
In March 1999, just three months before the FDA gave its blessing to the ill-fated arthritis Drug Vioxx, Merck & Co. had everything in place for an award-winning marketing campaign. It was a clinical trial. At least it looked like one. In fact, according to four physicians in the Aug. 19 issue of the Annals of Internal Medicine , Merck's clinical trial had a purpose very different from the goal of rigorously assessing the effectiveness and safety of Vioxx — the blockbuster painkiller Drug that Merck withdrew from the market in September 2004 after it was linked to a possible doubling of a patient's risk of heart attack and stroke. The clinical trial known as ADVANTAGE was a "seeding trial," write the four authors — all of whom have served as expert witnesses in court cases brought against Merck in connection with Vioxx. It was designed, they write, to speed and increase the rate at which doctors accepted and prescribed the new Drug, to gather inspiring "patient stories" for future use by reporters and marketers, and to court the goodwill of front-line physicians with the promise of professional prestige, research funds and the chance to be among the first to try a vaunted new remedy for an age-old scourge. Gadflies and watchdogs have long charged that Drug makers routinely drum up "seeding trials" in order to spread financial largesse to favored doctors and boost what's known in Drug marketing as the "uptake" of a new product by patien ...
Boston (dbTechno) - A cholesterol Drug from Schering-Plough Corp and Merck known as Vytorin has failed to lower the risk of major heart valve problems in a study. The Drug Vytorin is a combination of two cholesterol medications, Zetia as well as Zocor. The trial, called Enhance, revealed that the rate at which artery-clogging plaques formed in [...] ...